Connor, Clark & Lunn Investment Management (CC&L)’s Cytek Biosciences CTKB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18M	Buy	266,938 +25,434	+11%	+$109K	﹤0.01%	1148
2026 Q1	$1.06M	Sell	241,504 -54,132	-18%	-$256K	﹤0.01%	1144
2025 Q4	$1.49M	Sell	295,636 -2,239	-0.8%	-$10.4K	﹤0.01%	1010
2025 Q3	$1.03M	Sell	297,875 -21,191	-7%	-$79.5K	﹤0.01%	1055
2025 Q2	$1.08M	Sell	319,066 -40,511	-11%	-$135K	﹤0.01%	1025
2025 Q1	$1.44M	Sell	359,577 -242,118	-40%	-$1.25M	0.01%	827
2024 Q4	$3.91M	Sell	601,695 -13,935	-2%	-$83K	0.02%	552
2024 Q3	$3.41M	Sell	615,630 -15,842	-3%	-$89.8K	0.02%	538
2024 Q2	$3.52M	Sell	631,472 -486	-0.1%	-$2.92K	0.01%	513
2024 Q1	$4.24M	Buy	631,958 +107,245	+20%	+$848K	0.02%	470
2023 Q4	$4.79M	Buy	524,713 +296,318	+130%	+$1.86M	0.02%	433
2023 Q3	$1.26M	Buy	+228,395	New	+$1.83M	0.01%	746

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CTKB Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Cytek Biosciences (CTKB) stake by 11% in Q2 2026, buying an estimated $109K and bringing the position to 266,938 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CTKB in Q3 2023 and has held it in 12 quarters since. The position peaked at $4.79M in Q4 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 266,938 shares of Cytek Biosciences worth $1.18M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 25,434 Cytek Biosciences shares in Q2 2026, an estimated $109K.
Cytek Biosciences made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1148 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cytek Biosciences in Q3 2023 and has held it in 12 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Cytek Biosciences position peaked at $4.79M in Q4 2023.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.